Over the past four decades tamoxifen (Tam) has been extensively used in neoadjuvant and adjuvant settings for the treatment of hormonal dependent breast cancers by acting as a competitive inhibitor of ER.3, 4, 5 The benefits gained from the treatment are limited by development of either de novo or acquired resistance following a period of response to Tam. This evidence concerns the gene ESR1 and breast cancer.